Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome from Non-Controlling InterestsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income - MinorityNet Income towards Common StockholdersOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Cumberland Pharmaceuticals (CPIX) Gross Profit (2016 - 2025)

Cumberland Pharmaceuticals' Gross Profit history spans 16 years, with the latest figure at -$993639.0 for Q4 2025.

  • For Q4 2025, Gross Profit rose 51.55% year-over-year to -$993639.0; the TTM value through Dec 2025 reached $25.4 million, up 43.65%, while the annual FY2025 figure was $25.4 million, 21.96% up from the prior year.
  • Gross Profit for Q4 2025 was -$993639.0 at Cumberland Pharmaceuticals, down from $7.3 million in the prior quarter.
  • Across five years, Gross Profit topped out at $13.3 million in Q4 2022 and bottomed at -$2.1 million in Q4 2024.
  • The 5-year median for Gross Profit is $6.7 million (2021), against an average of $5.8 million.
  • The largest annual shift saw Gross Profit crashed 118.17% in 2021 before it skyrocketed 1198.47% in 2022.
  • A 5-year view of Gross Profit shows it stood at -$1.2 million in 2021, then surged by 1198.47% to $13.3 million in 2022, then crashed by 62.76% to $4.9 million in 2023, then tumbled by 141.45% to -$2.1 million in 2024, then skyrocketed by 51.55% to -$993639.0 in 2025.
  • Per Business Quant, the three most recent readings for CPIX's Gross Profit are -$993639.0 (Q4 2025), $7.3 million (Q3 2025), and $11.6 million (Q2 2025).